Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Omnipod 5 (Horizon) Tubeless Close-Loop Insulin Pump Test
29 views
Skip to first unread message
_
Mar 20, 2021, 9:31:31 PM3/20/21
to
This device, scheduled to be released in
the last half of 2021.
The Omnipod 5 System underwent three
months of at-home testing in
o 128 adults and adolescents ages 14 to
70 years (actual ages 20.5 to 65.5)
and
o 112 children ages 6 to less than 14 years.
(actual ages, 6.6 to 13.4)
Why age 14-17 was included with adults
rather than children, don't know, but as it
turns out, the youngest Adult was 20.5
years young. No one age 14 to 19 was
included in the study.
I found the following study after reading
a brief report about the study which had
far less detail.
As typically happens in studies, individuals
who have HbA1c levels < 5.7 are ignored.
Here are the HbA1c levels of participants
before the Omnipod 5 (Horizon) was used:
Children mean: 7.8 (6.7–9.6)
Adults mean: 7.1 (5.9–8.9)
- - -
January 18 2021
First Outpatient Evaluation of a Tubeless
Closed Loop Omnipod 5 (Horizon), Basal
Insulin Auto-Managed with Dexcom 6 CGM,
Automated Insulin Delivery System with
Customizable Glucose Targets in Children
and Adults with Insulinitis
https://www.liebertpub.com/doi/10.1089/dia.2020.0546
- - -
Insulinitis (Islit, near-total to total loss of
endogenous insulin).
Using my Omnipod 4 and a separate
Dexcom G6 CGM, here are my results
for the last 90 days for comparison to
the results displayed for Standard Ther-
apy & Omnipod 5 Horizon Therapy below.
Mean Sensor Glucose: 129 mg/dl
< 70 mg/dl: 1.3%
70-180 mg/dl: 90.7%
> 180 mg/dl: 8%
Latest HbA1c: 5.4
~~~
Detailed results: ST = Standard Therapy
HCL = Hybrid Closed Loop Therapy, i.e.
Omnipod 5 (Horizon) Therapy
https://www.liebertpub.com/na101/home/literatum/publisher/mal/journals/content/dia/0/dia.ahead-of-print/dia.2020.0546/20210117/images/medium/dia.2020.0546_inline2.jpg
Mean Sensor Glucose: Children 173 mg/dl to 183 mg/dl,
Adults 154 mg/dl to 170 mg/dl, much higher than my levels
of 129 mg/dl
< 70 mg/dl: Children were .5% to .8%, lower than my 1.3%,
Adults were .6% to 1.4%, higher than my 1.3% only when
their target glucose was 130 mg/dl
70-180 mg/dl: 53.5% to 75.1%, much lower than my 90.7%
> 180 mg/dl: Alarmingly high 23.4% to 46.7%, much higher
than my 8%
So, unless the Omnipod 5 (Horizon) can
mate to the glucose levels I have now,
I'd be hard pressed to use it, albeit I'd
enjoy being able to sleep without waking
up 4 times each night, but I'd fear its ap-
parent propensity for much higher glucose
levels than I'm able to achieve now.
I'd probably have to override whatever set-
tings they used in their test, because their
time in range is far lower than what I have
now and their time > 180 mg/dl is much
higher than what I have now, unacceptably
higher.
I have to add, see the following post for
details on what the glucose levels are of
individuals with a fully functional pancreas,
and note that my glucose levels, while
considerably better than the Omnipod 5
(Horizon) glucose levels, mine are ...
... disappointingly short of the perfectly
controlled glucose levels that those with
a fully functional pancreas achieve with-
out one iota of effort on their part.
https://groups.google.com/g/misc.health.diabetes/c/4E_1OM3ZzSk/m/LIj0zVsWAwAJ
Put another way, I'm disappointed in what I
see for the closed-loop Omnipod 5 (Horizon),
and Islit individuals need something far better
to have glucose levels like what we had prior
to Insulitis destroying our beta cells (the pri-
mary cause of Islit, but other infrequent ...
... causes can result in the near-total to total
loss of endogenous insulin).
~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
INSULINITIS (ISLIT)
New SUPERIOR clarifying name for near-
total to total loss of endogenous insulin
https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg
The overwhelming majority of Islit caused by
autoimmune attacks on pancreatic beta cells
(Insulitis Islit) but there are
o 13 specific types of rapid onset Islit, a
rare condition (only present in < one-half
of 1% of Americans & in a much lower rate
in most of the world), when present is typ-
ically diagnosed at age under 30
(50% at age < 18, 20% at age 19 to 29)
o 1 slow onset specific type, Latent Autoim-
mune Islit, frequency unknown but per a
recent report, misdiagnosed as Cellosis
(new clarifying name for type 2 diabetes)
almost 40% of the time due to its slow
onset and its occurrence typically at age
over 30
Old outdated anachronistic name for Islit is
type 1 diabetes, confusing in that diabetes
without clarifier is often used to describe
this condition which is 1 of the 7 Disparate
High Glucose Conditions (DHGCs).
That makes figuring out which DHGC is actu-
ally being referred to (and it can be any one,
or some, or all of them when the diabetes
or diabetic word is used without clarifier)
confusing / difficult:
https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg
https://prohuman.net/pix2/diabetesdiabeticconfusion.jpg
https://prohuman.net/pix2/diabetesdiabeticendingthemisunderstanding.jpg
- - -
Insulin / Insulin Pump / CGM I use
Fiasp Ultra-Fast-Acting Insulin in a
tubeless Omnipod insulin pump catheter
placed into skin / pod with adhesive
stuck onto skin every 80 hours, control
via PDM (Personal Data Manager)
https://prohuman.net/pix2/Fiaspinsulin_tubelessOmnipodDASHinsulinpump.jpg
Dexcom G6 CGM (continuous glucose monitor)
https://prohuman.net/pix2/Dexcom_G6_CGM.jpg
~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
the last half of 2021.
The Omnipod 5 System underwent three
months of at-home testing in
o 128 adults and adolescents ages 14 to
70 years (actual ages 20.5 to 65.5)
and
o 112 children ages 6 to less than 14 years.
(actual ages, 6.6 to 13.4)
Why age 14-17 was included with adults
rather than children, don't know, but as it
turns out, the youngest Adult was 20.5
years young. No one age 14 to 19 was
included in the study.
I found the following study after reading
a brief report about the study which had
far less detail.
As typically happens in studies, individuals
who have HbA1c levels < 5.7 are ignored.
Here are the HbA1c levels of participants
before the Omnipod 5 (Horizon) was used:
Children mean: 7.8 (6.7–9.6)
Adults mean: 7.1 (5.9–8.9)
- - -
January 18 2021
First Outpatient Evaluation of a Tubeless
Closed Loop Omnipod 5 (Horizon), Basal
Insulin Auto-Managed with Dexcom 6 CGM,
Automated Insulin Delivery System with
Customizable Glucose Targets in Children
and Adults with Insulinitis
https://www.liebertpub.com/doi/10.1089/dia.2020.0546
- - -
Insulinitis (Islit, near-total to total loss of
endogenous insulin).
Using my Omnipod 4 and a separate
Dexcom G6 CGM, here are my results
for the last 90 days for comparison to
the results displayed for Standard Ther-
apy & Omnipod 5 Horizon Therapy below.
Mean Sensor Glucose: 129 mg/dl
< 70 mg/dl: 1.3%
70-180 mg/dl: 90.7%
> 180 mg/dl: 8%
Latest HbA1c: 5.4
~~~
Detailed results: ST = Standard Therapy
HCL = Hybrid Closed Loop Therapy, i.e.
Omnipod 5 (Horizon) Therapy
https://www.liebertpub.com/na101/home/literatum/publisher/mal/journals/content/dia/0/dia.ahead-of-print/dia.2020.0546/20210117/images/medium/dia.2020.0546_inline2.jpg
Mean Sensor Glucose: Children 173 mg/dl to 183 mg/dl,
Adults 154 mg/dl to 170 mg/dl, much higher than my levels
of 129 mg/dl
< 70 mg/dl: Children were .5% to .8%, lower than my 1.3%,
Adults were .6% to 1.4%, higher than my 1.3% only when
their target glucose was 130 mg/dl
70-180 mg/dl: 53.5% to 75.1%, much lower than my 90.7%
> 180 mg/dl: Alarmingly high 23.4% to 46.7%, much higher
than my 8%
So, unless the Omnipod 5 (Horizon) can
mate to the glucose levels I have now,
I'd be hard pressed to use it, albeit I'd
enjoy being able to sleep without waking
up 4 times each night, but I'd fear its ap-
parent propensity for much higher glucose
levels than I'm able to achieve now.
I'd probably have to override whatever set-
tings they used in their test, because their
time in range is far lower than what I have
now and their time > 180 mg/dl is much
higher than what I have now, unacceptably
higher.
I have to add, see the following post for
details on what the glucose levels are of
individuals with a fully functional pancreas,
and note that my glucose levels, while
considerably better than the Omnipod 5
(Horizon) glucose levels, mine are ...
... disappointingly short of the perfectly
controlled glucose levels that those with
a fully functional pancreas achieve with-
out one iota of effort on their part.
https://groups.google.com/g/misc.health.diabetes/c/4E_1OM3ZzSk/m/LIj0zVsWAwAJ
Put another way, I'm disappointed in what I
see for the closed-loop Omnipod 5 (Horizon),
and Islit individuals need something far better
to have glucose levels like what we had prior
to Insulitis destroying our beta cells (the pri-
mary cause of Islit, but other infrequent ...
... causes can result in the near-total to total
loss of endogenous insulin).
~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
INSULINITIS (ISLIT)
New SUPERIOR clarifying name for near-
total to total loss of endogenous insulin
https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg
The overwhelming majority of Islit caused by
autoimmune attacks on pancreatic beta cells
(Insulitis Islit) but there are
o 13 specific types of rapid onset Islit, a
rare condition (only present in < one-half
of 1% of Americans & in a much lower rate
in most of the world), when present is typ-
ically diagnosed at age under 30
(50% at age < 18, 20% at age 19 to 29)
o 1 slow onset specific type, Latent Autoim-
mune Islit, frequency unknown but per a
recent report, misdiagnosed as Cellosis
(new clarifying name for type 2 diabetes)
almost 40% of the time due to its slow
onset and its occurrence typically at age
over 30
Old outdated anachronistic name for Islit is
type 1 diabetes, confusing in that diabetes
without clarifier is often used to describe
this condition which is 1 of the 7 Disparate
High Glucose Conditions (DHGCs).
That makes figuring out which DHGC is actu-
ally being referred to (and it can be any one,
or some, or all of them when the diabetes
or diabetic word is used without clarifier)
confusing / difficult:
https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg
https://prohuman.net/pix2/diabetesdiabeticconfusion.jpg
https://prohuman.net/pix2/diabetesdiabeticendingthemisunderstanding.jpg
- - -
Insulin / Insulin Pump / CGM I use
Fiasp Ultra-Fast-Acting Insulin in a
tubeless Omnipod insulin pump catheter
placed into skin / pod with adhesive
stuck onto skin every 80 hours, control
via PDM (Personal Data Manager)
https://prohuman.net/pix2/Fiaspinsulin_tubelessOmnipodDASHinsulinpump.jpg
Dexcom G6 CGM (continuous glucose monitor)
https://prohuman.net/pix2/Dexcom_G6_CGM.jpg
~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
_
Jun 24, 2021, 2:38:47 PM6/24/21
to
Follow-up:
Per the following, Insulet (maker of Omnipod)
plans to release a new study on June 26 2021
of Preschool Children and Adults using the
Omnipod® 5 System:
https://www.biospace.com/article/releases/insulet-to-present-new-clinical-data-for-preschool-children-and-adults-using-the-omnipod-5-system/
I expect the results will be disappointing for the
tiny minority of Islit individuals who currently have
HbA1c levels < 5.7, but hey, we'll soon see if the
study shows any indication anyone using the new
Omnipod 5 has glucose levels anywhere near to
what I have on manual pilot using the Omnipod 4
+ Dexcom G6.
The previous study referenced below didn't show
any sign of anyone having HbA1c levels < 5.7 when
using the Omnipod 5, displaying disappointing aver-
age glucose levels, hyperglycemia%s, & time 'tween
70 to 180 mg/dl. The only thing they excelled at was
lowering the hypoglycemia%.
The article above, disappointing in that it says that
Insulet "... expects to launch Omnipod 5 in limited
release during the second half of 2021. ..."
So, it's patience-required time for Islit individuals
in the U.S. who are interested in the Omnipod 5,
Dexcom G7, & Abbott Freestyle Libre 3, their avail-
ability in the U.S. probably not transpiring 'til 2022
(hopefully they'll surprise me by appearing late in
2021, but unlikely to be here 'til sometime in 2022).
On Saturday, March 20, 2021 at 8:31:31 PM UTC-5, _ wrote:
.> This device, scheduled to be released in
.> the last half of 2021.
.>
.> The Omnipod 5 System underwent three
.> months of at-home testing in
.>
.> o 128 adults and adolescents ages 14 to
.> 70 years (actual ages 20.5 to 65.5)
.>
.> and
.>
.> o 112 children ages 6 to less than 14 years.
.> (actual ages, 6.6 to 13.4)
.>
.> Why age 14-17 was included with adults
.> rather than children, don't know, but as it
.> turns out, the youngest Adult was 20.5
.> years young. No one age 14 to 19 was
.> included in the study.
.>
.> I found the following study after reading
.> a brief report about the study which had
.> far less detail.
.>
.> As typically happens in studies, individuals
.> who have HbA1c levels < 5.7 are ignored.
.> Here are the HbA1c levels of participants
.> before the Omnipod 5 (Horizon) was used:
.>
.> Children mean: 7.8 (6.7–9.6)
.> Adults mean: 7.1 (5.9–8.9)
.>
.> - - -
.> January 18 2021
.>
.> First Outpatient Evaluation of a Tubeless
.> Closed Loop Omnipod 5 (Horizon), Basal
.> Insulin Auto-Managed with Dexcom 6 CGM,
.> Automated Insulin Delivery System with
.> Customizable Glucose Targets in Children
.> and Adults with Insulinitis
.> https://www.liebertpub.com/doi/10.1089/dia.2020.0546
.> - - -
.>
.> Insulinitis (Islit, near-total to total loss of
.> endogenous insulin).
.>
.> Using my Omnipod 4 and a separate
.> Dexcom G6 CGM, here are my results
.> for the last 90 days for comparison to
.> the results displayed for Standard Ther-
.> apy & Omnipod 5 Horizon Therapy below.
.>
.> Mean Sensor Glucose: 129 mg/dl
.>
.> < 70 mg/dl: 1.3%
.>
.> 70-180 mg/dl: 90.7%
.>
.> > 180 mg/dl: 8%
.>
.> Latest HbA1c: 5.4
.>
.> ~~~
.>
.> Detailed results: ST = Standard Therapy
.> HCL = Hybrid Closed Loop Therapy, i.e.
.> Omnipod 5 (Horizon) Therapy
.> https://www.liebertpub.com/na101/home/literatum/publisher/mal/journals/content/dia/0/dia.ahead-of-print/dia.2020.0546/20210117/images/medium/dia.2020.0546_inline2.jpg
.>
.> Mean Sensor Glucose: Children 173 mg/dl to 183 mg/dl,
.> Adults 154 mg/dl to 170 mg/dl, much higher than my levels
.> of 129 mg/dl
.>
.> < 70 mg/dl: Children were .5% to .8%, lower than my 1.3%,
.> Adults were .6% to 1.4%, higher than my 1.3% only when
.> their target glucose was 130 mg/dl
.>
.> 70-180 mg/dl: 53.5% to 75.1%, much lower than my 90.7%
.>
.> > 180 mg/dl: Alarmingly high 23.4% to 46.7%, much higher
.> than my 8%
.>
.> So, unless the Omnipod 5 (Horizon) can
.> mate to the glucose levels I have now,
.> I'd be hard pressed to use it, albeit I'd
.> enjoy being able to sleep without waking
.> up 4 times each night, but I'd fear its ap-
.> parent propensity for much higher glucose
.> levels than I'm able to achieve now.
.>
.> I'd probably have to override whatever set-
.> tings they used in their test, because their
.> time in range is far lower than what I have
.> now and their time > 180 mg/dl is much
.> higher than what I have now, unacceptably
.> higher.
.>
.> I have to add, see the following post for
.> details on what the glucose levels are of
.> individuals with a fully functional pancreas,
.> and note that my glucose levels, while
.> considerably better than the Omnipod 5
.> (Horizon) glucose levels, mine are ...
.>
.> ... disappointingly short of the perfectly
.> controlled glucose levels that those with
.> a fully functional pancreas achieve with-
.> out one iota of effort on their part.
.> https://groups.google.com/g/misc.health.diabetes/c/4E_1OM3ZzSk/m/LIj0zVsWAwAJ
.>
.> Put another way, I'm disappointed in what I
.> see for the closed-loop Omnipod 5 (Horizon),
.> and Islit individuals need something far better
.> to have glucose levels like what we had prior
.> to Insulitis destroying our beta cells (the pri-
.> mary cause of Islit, but other infrequent ...
.>
.> ... causes can result in the near-total to total
.> loss of endogenous insulin).
.>
.> ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
.>
.> INSULINITIS (ISLIT)
.>
.> New SUPERIOR clarifying name for near-
.> total to total loss of endogenous insulin
.> https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg
.>
.> The overwhelming majority of Islit caused by
.> autoimmune attacks on pancreatic beta cells
.> (Insulitis Islit) but there are
.>
.> o 15 specific types of rapid onset Islit, a
.> rare condition (only present in < one-half
.> of 1% of Americans & in a much lower rate
.> in most of the world), when present is typ-
.> ically diagnosed at age under 30
.> (50% at age < 18, 20% at age 19 to 29)
.>
.> o 1 slow onset specific type, Latent Autoim-
.> mune Islit, frequency unknown but per a
.> recent report, misdiagnosed as Cellosis
.> (new clarifying name for type 2 diabetes)
.> almost 40% of the time due to its slow
.> onset and its occurrence typically at age
.> over 30
.>
.> Old outdated anachronistic name for Islit is
.> type 1 diabetes, confusing in that diabetes
.> without clarifier is often used to describe
.> this condition which is 1 of the 7 Disparate
.> High Glucose Conditions (DHGCs).
.>
.> That makes figuring out which DHGC is actu-
.> ally being referred to (and it can be any one,
.> or some, or all of them when the diabetes
.> or diabetic word is used without clarifier)
.> confusing / difficult:
.> https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg
.> https://prohuman.net/pix2/diabetesdiabeticconfusion.jpg
.> https://prohuman.net/pix2/diabetesdiabeticendingthemisunderstanding.jpg
.>
.> - - -
.>
.> Insulin / Insulin Pump / CGM I use
.>
.> Fiasp Ultra-Fast-Acting Insulin in a
.> tubeless Omnipod insulin pump catheter
.> placed into skin / pod with adhesive
.> stuck onto skin every 80 hours, control
.> via PDM (Personal Data Manager)
.> https://prohuman.net/pix2/Fiaspinsulin_tubelessOmnipodDASHinsulinpump.jpg
.>
.> Dexcom G6 CGM (continuous glucose monitor)
.> https://prohuman.net/pix2/Dexcom_G6_CGM.jpg
.>
.> ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
Per the following, Insulet (maker of Omnipod)
plans to release a new study on June 26 2021
of Preschool Children and Adults using the
Omnipod® 5 System:
https://www.biospace.com/article/releases/insulet-to-present-new-clinical-data-for-preschool-children-and-adults-using-the-omnipod-5-system/
I expect the results will be disappointing for the
tiny minority of Islit individuals who currently have
HbA1c levels < 5.7, but hey, we'll soon see if the
study shows any indication anyone using the new
Omnipod 5 has glucose levels anywhere near to
what I have on manual pilot using the Omnipod 4
+ Dexcom G6.
The previous study referenced below didn't show
any sign of anyone having HbA1c levels < 5.7 when
using the Omnipod 5, displaying disappointing aver-
age glucose levels, hyperglycemia%s, & time 'tween
70 to 180 mg/dl. The only thing they excelled at was
lowering the hypoglycemia%.
The article above, disappointing in that it says that
Insulet "... expects to launch Omnipod 5 in limited
release during the second half of 2021. ..."
So, it's patience-required time for Islit individuals
in the U.S. who are interested in the Omnipod 5,
Dexcom G7, & Abbott Freestyle Libre 3, their avail-
ability in the U.S. probably not transpiring 'til 2022
(hopefully they'll surprise me by appearing late in
2021, but unlikely to be here 'til sometime in 2022).
On Saturday, March 20, 2021 at 8:31:31 PM UTC-5, _ wrote:
.> This device, scheduled to be released in
.> the last half of 2021.
.>
.> The Omnipod 5 System underwent three
.> months of at-home testing in
.>
.> o 128 adults and adolescents ages 14 to
.> 70 years (actual ages 20.5 to 65.5)
.>
.> and
.>
.> o 112 children ages 6 to less than 14 years.
.> (actual ages, 6.6 to 13.4)
.>
.> Why age 14-17 was included with adults
.> rather than children, don't know, but as it
.> turns out, the youngest Adult was 20.5
.> years young. No one age 14 to 19 was
.> included in the study.
.>
.> I found the following study after reading
.> a brief report about the study which had
.> far less detail.
.>
.> As typically happens in studies, individuals
.> who have HbA1c levels < 5.7 are ignored.
.> Here are the HbA1c levels of participants
.> before the Omnipod 5 (Horizon) was used:
.>
.> Children mean: 7.8 (6.7–9.6)
.> Adults mean: 7.1 (5.9–8.9)
.>
.> - - -
.> January 18 2021
.>
.> First Outpatient Evaluation of a Tubeless
.> Closed Loop Omnipod 5 (Horizon), Basal
.> Insulin Auto-Managed with Dexcom 6 CGM,
.> Automated Insulin Delivery System with
.> Customizable Glucose Targets in Children
.> and Adults with Insulinitis
.> https://www.liebertpub.com/doi/10.1089/dia.2020.0546
.> - - -
.>
.> Insulinitis (Islit, near-total to total loss of
.> endogenous insulin).
.>
.> Using my Omnipod 4 and a separate
.> Dexcom G6 CGM, here are my results
.> for the last 90 days for comparison to
.> the results displayed for Standard Ther-
.> apy & Omnipod 5 Horizon Therapy below.
.>
.> Mean Sensor Glucose: 129 mg/dl
.>
.> < 70 mg/dl: 1.3%
.>
.> 70-180 mg/dl: 90.7%
.>
.> > 180 mg/dl: 8%
.>
.> Latest HbA1c: 5.4
.>
.> ~~~
.>
.> Detailed results: ST = Standard Therapy
.> HCL = Hybrid Closed Loop Therapy, i.e.
.> Omnipod 5 (Horizon) Therapy
.> https://www.liebertpub.com/na101/home/literatum/publisher/mal/journals/content/dia/0/dia.ahead-of-print/dia.2020.0546/20210117/images/medium/dia.2020.0546_inline2.jpg
.>
.> Mean Sensor Glucose: Children 173 mg/dl to 183 mg/dl,
.> Adults 154 mg/dl to 170 mg/dl, much higher than my levels
.> of 129 mg/dl
.>
.> < 70 mg/dl: Children were .5% to .8%, lower than my 1.3%,
.> Adults were .6% to 1.4%, higher than my 1.3% only when
.> their target glucose was 130 mg/dl
.>
.> 70-180 mg/dl: 53.5% to 75.1%, much lower than my 90.7%
.>
.> > 180 mg/dl: Alarmingly high 23.4% to 46.7%, much higher
.> than my 8%
.>
.> So, unless the Omnipod 5 (Horizon) can
.> mate to the glucose levels I have now,
.> I'd be hard pressed to use it, albeit I'd
.> enjoy being able to sleep without waking
.> up 4 times each night, but I'd fear its ap-
.> parent propensity for much higher glucose
.> levels than I'm able to achieve now.
.>
.> I'd probably have to override whatever set-
.> tings they used in their test, because their
.> time in range is far lower than what I have
.> now and their time > 180 mg/dl is much
.> higher than what I have now, unacceptably
.> higher.
.>
.> I have to add, see the following post for
.> details on what the glucose levels are of
.> individuals with a fully functional pancreas,
.> and note that my glucose levels, while
.> considerably better than the Omnipod 5
.> (Horizon) glucose levels, mine are ...
.>
.> ... disappointingly short of the perfectly
.> controlled glucose levels that those with
.> a fully functional pancreas achieve with-
.> out one iota of effort on their part.
.> https://groups.google.com/g/misc.health.diabetes/c/4E_1OM3ZzSk/m/LIj0zVsWAwAJ
.>
.> Put another way, I'm disappointed in what I
.> see for the closed-loop Omnipod 5 (Horizon),
.> and Islit individuals need something far better
.> to have glucose levels like what we had prior
.> to Insulitis destroying our beta cells (the pri-
.> mary cause of Islit, but other infrequent ...
.>
.> ... causes can result in the near-total to total
.> loss of endogenous insulin).
.>
.> ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
.>
.> INSULINITIS (ISLIT)
.>
.> New SUPERIOR clarifying name for near-
.> total to total loss of endogenous insulin
.> https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg
.>
.> The overwhelming majority of Islit caused by
.> autoimmune attacks on pancreatic beta cells
.> (Insulitis Islit) but there are
.>
.> o 15 specific types of rapid onset Islit, a
.> rare condition (only present in < one-half
.> of 1% of Americans & in a much lower rate
.> in most of the world), when present is typ-
.> ically diagnosed at age under 30
.> (50% at age < 18, 20% at age 19 to 29)
.>
.> o 1 slow onset specific type, Latent Autoim-
.> mune Islit, frequency unknown but per a
.> recent report, misdiagnosed as Cellosis
.> (new clarifying name for type 2 diabetes)
.> almost 40% of the time due to its slow
.> onset and its occurrence typically at age
.> over 30
.>
.> Old outdated anachronistic name for Islit is
.> type 1 diabetes, confusing in that diabetes
.> without clarifier is often used to describe
.> this condition which is 1 of the 7 Disparate
.> High Glucose Conditions (DHGCs).
.>
.> That makes figuring out which DHGC is actu-
.> ally being referred to (and it can be any one,
.> or some, or all of them when the diabetes
.> or diabetic word is used without clarifier)
.> confusing / difficult:
.> https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg
.> https://prohuman.net/pix2/diabetesdiabeticconfusion.jpg
.> https://prohuman.net/pix2/diabetesdiabeticendingthemisunderstanding.jpg
.>
.> - - -
.>
.> Insulin / Insulin Pump / CGM I use
.>
.> Fiasp Ultra-Fast-Acting Insulin in a
.> tubeless Omnipod insulin pump catheter
.> placed into skin / pod with adhesive
.> stuck onto skin every 80 hours, control
.> via PDM (Personal Data Manager)
.> https://prohuman.net/pix2/Fiaspinsulin_tubelessOmnipodDASHinsulinpump.jpg
.>
.> Dexcom G6 CGM (continuous glucose monitor)
.> https://prohuman.net/pix2/Dexcom_G6_CGM.jpg
.>
.> ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
_
Jun 26, 2021, 5:55:32 PM6/26/21
to
Follow-up 2:
Unlike the plethora of details in the original
post in this thread, the following report has
a few sparse details. I expect a plethora of
details will appear in the future.
Odd, they don't mention the critical continu-
ous glucose monitor tie-in to the Omnipod 5,
using a term I haven't seen before, Automated
Insulin Delivery (AID) System, not mentioning
that to auto-adjust basal insulin dosaging, the
glucose levels from a tied-in CGM are critical.
Another glaring shortcoming, they focus on
Islit individuals with high glucose levels in
their tests, ignoring Islit individuals whose
current glucose levels are < 7, < 6.5, < 6,
& < 5.7 (the good-to-great HbA1c gang).
I'm disappointed that they are so focused
on Islit individuals with HbA1c > 7 they ig-
nore Islit individuals with HbA1c levels men-
tioned. One would hope that those individuals
would also have significant benefits (less ...
... hypoglycemia, more time in range, less
hyperglycemia, as good or better HbA1c)
via Omnipod 5, but unfortunately, their test-
ing ignores the good-to-great-HbA1c gang.
- - -
June 26 2021
Insulet’s Omnipod® 5 Automated Insulin
Delivery (AID) System Pivotal Studies
Demonstrate Improved Outcomes Across
the Lifespan from Ages 2 to 70 years
https://www.businesswire.com/news/home/20210626005002/en/Insulet%E2%80%99s-Omnipod%C2%AE-5-Automated-Insulin-Delivery-System-Pivotal-Studies-Demonstrate-Improved-Outcomes-Across-the-Lifespan-from-Ages-2-to-70-years
- - -
... 80 preschool aged children across 10 U.S.
sites for this study. The participants, who were
between 2 and 5.9 years of age with an HbA1c
of under 10.0%, used Omnipod 5 at home for a
period of 3 months after a 14-day period using ...
... their standard therapy, which included either
pump therapy or multiple daily injections (MDI).
The children were unrestricted in eating and
exercise throughout the study.
The study showed an overall reduction in HbA1c
from an average of 7.4% to 6.9%, and a signifi-
cant increase in time in range (70-180 mg/dL),
from an average of 57.2% to 68.1%, or an addi-
tional 2.6 hours per day. Median time in hypo-
glycemia (<70 mg/dL) was reduced, from 2.2%
to 1.9% overall.
... subjective sleep quality. Parents and care-
givers reporting “very good” or “fairly good”
sleep increased from 65% at baseline to 90%
at the end of the study.
... 33 participants in the pivotal trial transitioning
from MDI to Omnipod 5 achieved significant im-
provement in HbA1c (children: 7.73% to 6.74%,
adolescents and adults: 7.57% to 6.97%) & time
in range (children: 52.2% to 68.9%; adolescents
& adults: 60.4% to 72.3%) after 3 months of use.
... 224 pivotal study participants continuing use
of Omnipod 5 in an extension study demonstrated
sustained improvements in HbA1c over a total of
6 months of system use.
Pediatric results decreased from an average of
7.7% at baseline to 6.9% at 6 months, and the
adolescent and adult cohort decreased from an
average of 7.2% to 6.7%. The extension study
also revealed sustained improvements in time in
range with minimal time below range.
,,, users perceived Omnipod 5 to be a more usable
product compared to their prior therapy.
Adults and caregivers of teens and children also
reported increased satisfaction with their treatment
... suggesting that Omnipod 5 may alleviate some
of the burdens associated with existing treatment
options for Islit both for adults and caregivers of
younger users.
Furthermore, Omnipod 5 led to significant improve-
ments in quality-of-life measures, including reduc-
tions in Islit-related distress across all groups, and
improved hypoglycemic confidence among adults
and caregivers of children.
As indicated by these outcomes, reduced Islit dis-
tress and improved quality of life are key benefits
of using the Omnipod 5 AID system that are com-
plementary to the glycemic benefits achieved. ...
On Thursday, June 24, 2021 at 1:38:47 PM UTC-5, _ wrote:
.> Follow-up:
.>
.> Per the following, Insulet (maker of Omnipod)
.> plans to release a new study on June 26 2021
.> of Preschool Children and Adults using the
.> Omnipod® 5 System:
.> https://www.biospace.com/article/releases/insulet-to-present-new-clinical-data-for-preschool-children-and-adults-using-the-omnipod-5-system/
.>
.> I expect the results will be disappointing for the
.> tiny minority of Islit individuals who currently have
.> HbA1c levels < 5.7, but hey, we'll soon see if the
.> study shows any indication anyone using the new
.> Omnipod 5 has glucose levels anywhere near to
.> what I have on manual pilot using the Omnipod 4
.> + Dexcom G6.
.>
.> The previous study referenced below didn't show
.> any sign of anyone having HbA1c levels < 5.7 when
.> using the Omnipod 5, displaying disappointing aver-
.> age glucose levels, hyperglycemia%s, & time 'tween
.> 70 to 180 mg/dl. The only thing they excelled at was
.> lowering the hypoglycemia%.
.>
.> The article above, disappointing in that it says that
.> Insulet "... expects to launch Omnipod 5 in limited
.> release during the second half of 2021. ..."
.>
.> So, it's patience-required time for Islit individuals
.> in the U.S. who are interested in the Omnipod 5,
.> Dexcom G7, & Abbott Freestyle Libre 3, their avail-
.> ability in the U.S. probably not transpiring 'til 2022
.> (hopefully they'll surprise me by appearing late in
.> 2021, but unlikely to be here 'til sometime in 2022).
/> On Saturday, March 20, 2021 at 8:31:31 PM UTC-5, _ wrote:
/> .> This device, scheduled to be released in
/> .> the last half of 2021.
/> .>
/> .> The Omnipod 5 System underwent three
/> .> months of at-home testing in
/> .>
/> .> o 128 adults and adolescents ages 14 to
/> .> 70 years (actual ages 20.5 to 65.5)
/> .>
/> .> and
/> .>
/> .> o 112 children ages 6 to less than 14 years.
/> .> (actual ages, 6.6 to 13.4)
/> .>
/> .> Why age 14-17 was included with adults
/> .> rather than children, don't know, but as it
/> .> turns out, the youngest Adult was 20.5
/> .> years young. No one age 14 to 19 was
/> .> included in the study.
/> .>
/> .> I found the following study after reading
/> .> a brief report about the study which had
/> .> far less detail.
/> .>
/> .> As typically happens in studies, individuals
/> .> who have HbA1c levels < 5.7 are ignored.
/> .> Here are the HbA1c levels of participants
/> .> before the Omnipod 5 (Horizon) was used:
/> .>
/> .> Children mean: 7.8 (6.7–9.6)
/> .> Adults mean: 7.1 (5.9–8.9)
/> .>
/> .> - - -
/> .> January 18 2021
/> .>
/> .> First Outpatient Evaluation of a Tubeless
/> .> Closed Loop Omnipod 5 (Horizon), Basal
/> .> Insulin Auto-Managed with Dexcom 6 CGM,
/> .> Automated Insulin Delivery System with
/> .> Customizable Glucose Targets in Children
/> .> and Adults with Insulinitis
/> .> https://www.liebertpub.com/doi/10.1089/dia.2020.0546
/> .> - - -
/> .>
/> .> Insulinitis (Islit, near-total to total loss of
/> .> endogenous insulin).
/> .>
/> .> Using my Omnipod 4 and a separate
/> .> Dexcom G6 CGM, here are my results
/> .> for the last 90 days for comparison to
/> .> the results displayed for Standard Ther-
/> .> apy & Omnipod 5 Horizon Therapy below.
/> .>
/> .> Mean Sensor Glucose: 129 mg/dl
/> .>
/> .> < 70 mg/dl: 1.3%
/> .>
/> .> 70-180 mg/dl: 90.7%
/> .>
/> .> > 180 mg/dl: 8%
/> .>
/> .> Latest HbA1c: 5.4
/> .>
/> .> ~~~
/> .>
/> .> Detailed results: ST = Standard Therapy
/> .> HCL = Hybrid Closed Loop Therapy, i.e.
/> .> Omnipod 5 (Horizon) Therapy
/> .> https://www.liebertpub.com/na101/home/literatum/publisher/mal/journals/content/dia/0/dia.ahead-of-print/dia.2020.0546/20210117/images/medium/dia.2020.0546_inline2.jpg
/> .>
/> .> Mean Sensor Glucose: Children 173 mg/dl to 183 mg/dl,
/> .> Adults 154 mg/dl to 170 mg/dl, much higher than my levels
/> .> of 129 mg/dl
/> .>
/> .> < 70 mg/dl: Children were .5% to .8%, lower than my 1.3%,
/> .> Adults were .6% to 1.4%, higher than my 1.3% only when
/> .> their target glucose was 130 mg/dl
/> .>
/> .> 70-180 mg/dl: 53.5% to 75.1%, much lower than my 90.7%
/> .>
/> .> > 180 mg/dl: Alarmingly high 23.4% to 46.7%, much higher
/> .> than my 8%
/> .>
/> .> So, unless the Omnipod 5 (Horizon) can
/> .> mate to the glucose levels I have now,
/> .> I'd be hard pressed to use it, albeit I'd
/> .> enjoy being able to sleep without waking
/> .> up 4 times each night, but I'd fear its ap-
/> .> parent propensity for much higher glucose
/> .> levels than I'm able to achieve now.
/> .>
/> .> I'd probably have to override whatever set-
/> .> tings they used in their test, because their
/> .> time in range is far lower than what I have
/> .> now and their time > 180 mg/dl is much
/> .> higher than what I have now, unacceptably
/> .> higher.
/> .>
/> .> I have to add, see the following post for
/> .> details on what the glucose levels are of
/> .> individuals with a fully functional pancreas,
/> .> and note that my glucose levels, while
/> .> considerably better than the Omnipod 5
/> .> (Horizon) glucose levels, mine are ...
/> .>
/> .> ... disappointingly short of the perfectly
/> .> controlled glucose levels that those with
/> .> a fully functional pancreas achieve with-
/> .> out one iota of effort on their part.
/> .> https://groups.google.com/g/misc.health.diabetes/c/4E_1OM3ZzSk/m/LIj0zVsWAwAJ
/> .>
/> .> Put another way, I'm disappointed in what I
/> .> see for the closed-loop Omnipod 5 (Horizon),
/> .> and Islit individuals need something far better
/> .> to have glucose levels like what we had prior
/> .> to Insulitis destroying our beta cells (the pri-
/> .> mary cause of Islit, but other infrequent ...
/> .>
/> .> ... causes can result in the near-total to total
/> .> loss of endogenous insulin).
/> .>
/> .> ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
/> .>
/> .> INSULINITIS (ISLIT)
/> .>
/> .> New SUPERIOR clarifying name for near-
/> .> total to total loss of endogenous insulin
/> .> https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg
/> .>
/> .> The overwhelming majority of Islit caused by
/> .> autoimmune attacks on pancreatic beta cells
/> .> (Insulitis Islit) but there are
/> .>
/> .> o 15 specific types of rapid onset Islit, a
/> .> rare condition (only present in < one-half
/> .> of 1% of Americans & in a much lower rate
/> .> in most of the world), when present is typ-
/> .> ically diagnosed at age under 30
/> .> (50% at age < 18, 20% at age 19 to 29)
/> .>
/> .> o 1 slow onset specific type, Latent Autoim-
/> .> mune Islit, frequency unknown but per a
/> .> recent report, misdiagnosed as Cellosis
/> .> (new clarifying name for type 2 diabetes)
/> .> almost 40% of the time due to its slow
/> .> onset and its occurrence typically at age
/> .> over 30
/> .>
/> .> Old outdated anachronistic name for Islit is
/> .> type 1 diabetes, confusing in that diabetes
/> .> without clarifier is often used to describe
/> .> this condition which is 1 of the 7 Disparate
/> .> High Glucose Conditions (DHGCs).
/> .>
/> .> That makes figuring out which DHGC is actu-
/> .> ally being referred to (and it can be any one,
/> .> or some, or all of them when the diabetes
/> .> or diabetic word is used without clarifier)
/> .> confusing / difficult:
/> .> https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg
/> .> https://prohuman.net/pix2/diabetesdiabeticconfusion.jpg
/> .> https://prohuman.net/pix2/diabetesdiabeticendingthemisunderstanding.jpg
/> .>
/> .> - - -
/> .>
/> .> Insulin / Insulin Pump / CGM I use
/> .>
/> .> Fiasp Ultra-Fast-Acting Insulin in a
/> .> tubeless Omnipod insulin pump catheter
/> .> placed into skin / pod with adhesive
/> .> stuck onto skin every 80 hours, control
/> .> via PDM (Personal Data Manager)
/> .> https://prohuman.net/pix2/Fiaspinsulin_tubelessOmnipodDASHinsulinpump.jpg
/> .>
/> .> Dexcom G6 CGM (continuous glucose monitor)
/> .> https://prohuman.net/pix2/Dexcom_G6_CGM.jpg
/> .>
/> .> ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
Unlike the plethora of details in the original
post in this thread, the following report has
a few sparse details. I expect a plethora of
details will appear in the future.
Odd, they don't mention the critical continu-
ous glucose monitor tie-in to the Omnipod 5,
using a term I haven't seen before, Automated
Insulin Delivery (AID) System, not mentioning
that to auto-adjust basal insulin dosaging, the
glucose levels from a tied-in CGM are critical.
Another glaring shortcoming, they focus on
Islit individuals with high glucose levels in
their tests, ignoring Islit individuals whose
current glucose levels are < 7, < 6.5, < 6,
& < 5.7 (the good-to-great HbA1c gang).
I'm disappointed that they are so focused
on Islit individuals with HbA1c > 7 they ig-
nore Islit individuals with HbA1c levels men-
tioned. One would hope that those individuals
would also have significant benefits (less ...
... hypoglycemia, more time in range, less
hyperglycemia, as good or better HbA1c)
via Omnipod 5, but unfortunately, their test-
ing ignores the good-to-great-HbA1c gang.
- - -
June 26 2021
Insulet’s Omnipod® 5 Automated Insulin
Delivery (AID) System Pivotal Studies
Demonstrate Improved Outcomes Across
the Lifespan from Ages 2 to 70 years
https://www.businesswire.com/news/home/20210626005002/en/Insulet%E2%80%99s-Omnipod%C2%AE-5-Automated-Insulin-Delivery-System-Pivotal-Studies-Demonstrate-Improved-Outcomes-Across-the-Lifespan-from-Ages-2-to-70-years
- - -
... 80 preschool aged children across 10 U.S.
sites for this study. The participants, who were
between 2 and 5.9 years of age with an HbA1c
of under 10.0%, used Omnipod 5 at home for a
period of 3 months after a 14-day period using ...
... their standard therapy, which included either
pump therapy or multiple daily injections (MDI).
The children were unrestricted in eating and
exercise throughout the study.
The study showed an overall reduction in HbA1c
from an average of 7.4% to 6.9%, and a signifi-
cant increase in time in range (70-180 mg/dL),
from an average of 57.2% to 68.1%, or an addi-
tional 2.6 hours per day. Median time in hypo-
glycemia (<70 mg/dL) was reduced, from 2.2%
to 1.9% overall.
... subjective sleep quality. Parents and care-
givers reporting “very good” or “fairly good”
sleep increased from 65% at baseline to 90%
at the end of the study.
... 33 participants in the pivotal trial transitioning
from MDI to Omnipod 5 achieved significant im-
provement in HbA1c (children: 7.73% to 6.74%,
adolescents and adults: 7.57% to 6.97%) & time
in range (children: 52.2% to 68.9%; adolescents
& adults: 60.4% to 72.3%) after 3 months of use.
... 224 pivotal study participants continuing use
of Omnipod 5 in an extension study demonstrated
sustained improvements in HbA1c over a total of
6 months of system use.
Pediatric results decreased from an average of
7.7% at baseline to 6.9% at 6 months, and the
adolescent and adult cohort decreased from an
average of 7.2% to 6.7%. The extension study
also revealed sustained improvements in time in
range with minimal time below range.
,,, users perceived Omnipod 5 to be a more usable
product compared to their prior therapy.
Adults and caregivers of teens and children also
reported increased satisfaction with their treatment
... suggesting that Omnipod 5 may alleviate some
of the burdens associated with existing treatment
options for Islit both for adults and caregivers of
younger users.
Furthermore, Omnipod 5 led to significant improve-
ments in quality-of-life measures, including reduc-
tions in Islit-related distress across all groups, and
improved hypoglycemic confidence among adults
and caregivers of children.
As indicated by these outcomes, reduced Islit dis-
tress and improved quality of life are key benefits
of using the Omnipod 5 AID system that are com-
plementary to the glycemic benefits achieved. ...
On Thursday, June 24, 2021 at 1:38:47 PM UTC-5, _ wrote:
.> Follow-up:
.>
.> Per the following, Insulet (maker of Omnipod)
.> plans to release a new study on June 26 2021
.> of Preschool Children and Adults using the
.> Omnipod® 5 System:
.> https://www.biospace.com/article/releases/insulet-to-present-new-clinical-data-for-preschool-children-and-adults-using-the-omnipod-5-system/
.>
.> I expect the results will be disappointing for the
.> tiny minority of Islit individuals who currently have
.> HbA1c levels < 5.7, but hey, we'll soon see if the
.> study shows any indication anyone using the new
.> Omnipod 5 has glucose levels anywhere near to
.> what I have on manual pilot using the Omnipod 4
.> + Dexcom G6.
.>
.> The previous study referenced below didn't show
.> any sign of anyone having HbA1c levels < 5.7 when
.> using the Omnipod 5, displaying disappointing aver-
.> age glucose levels, hyperglycemia%s, & time 'tween
.> 70 to 180 mg/dl. The only thing they excelled at was
.> lowering the hypoglycemia%.
.>
.> The article above, disappointing in that it says that
.> Insulet "... expects to launch Omnipod 5 in limited
.> release during the second half of 2021. ..."
.>
.> So, it's patience-required time for Islit individuals
.> in the U.S. who are interested in the Omnipod 5,
.> Dexcom G7, & Abbott Freestyle Libre 3, their avail-
.> ability in the U.S. probably not transpiring 'til 2022
.> (hopefully they'll surprise me by appearing late in
.> 2021, but unlikely to be here 'til sometime in 2022).
/> On Saturday, March 20, 2021 at 8:31:31 PM UTC-5, _ wrote:
/> .> This device, scheduled to be released in
/> .> the last half of 2021.
/> .>
/> .> The Omnipod 5 System underwent three
/> .> months of at-home testing in
/> .>
/> .> o 128 adults and adolescents ages 14 to
/> .> 70 years (actual ages 20.5 to 65.5)
/> .>
/> .> and
/> .>
/> .> o 112 children ages 6 to less than 14 years.
/> .> (actual ages, 6.6 to 13.4)
/> .>
/> .> Why age 14-17 was included with adults
/> .> rather than children, don't know, but as it
/> .> turns out, the youngest Adult was 20.5
/> .> years young. No one age 14 to 19 was
/> .> included in the study.
/> .>
/> .> I found the following study after reading
/> .> a brief report about the study which had
/> .> far less detail.
/> .>
/> .> As typically happens in studies, individuals
/> .> who have HbA1c levels < 5.7 are ignored.
/> .> Here are the HbA1c levels of participants
/> .> before the Omnipod 5 (Horizon) was used:
/> .>
/> .> Children mean: 7.8 (6.7–9.6)
/> .> Adults mean: 7.1 (5.9–8.9)
/> .>
/> .> - - -
/> .> January 18 2021
/> .>
/> .> First Outpatient Evaluation of a Tubeless
/> .> Closed Loop Omnipod 5 (Horizon), Basal
/> .> Insulin Auto-Managed with Dexcom 6 CGM,
/> .> Automated Insulin Delivery System with
/> .> Customizable Glucose Targets in Children
/> .> and Adults with Insulinitis
/> .> https://www.liebertpub.com/doi/10.1089/dia.2020.0546
/> .> - - -
/> .>
/> .> Insulinitis (Islit, near-total to total loss of
/> .> endogenous insulin).
/> .>
/> .> Using my Omnipod 4 and a separate
/> .> Dexcom G6 CGM, here are my results
/> .> for the last 90 days for comparison to
/> .> the results displayed for Standard Ther-
/> .> apy & Omnipod 5 Horizon Therapy below.
/> .>
/> .> Mean Sensor Glucose: 129 mg/dl
/> .>
/> .> < 70 mg/dl: 1.3%
/> .>
/> .> 70-180 mg/dl: 90.7%
/> .>
/> .> > 180 mg/dl: 8%
/> .>
/> .> Latest HbA1c: 5.4
/> .>
/> .> ~~~
/> .>
/> .> Detailed results: ST = Standard Therapy
/> .> HCL = Hybrid Closed Loop Therapy, i.e.
/> .> Omnipod 5 (Horizon) Therapy
/> .> https://www.liebertpub.com/na101/home/literatum/publisher/mal/journals/content/dia/0/dia.ahead-of-print/dia.2020.0546/20210117/images/medium/dia.2020.0546_inline2.jpg
/> .>
/> .> Mean Sensor Glucose: Children 173 mg/dl to 183 mg/dl,
/> .> Adults 154 mg/dl to 170 mg/dl, much higher than my levels
/> .> of 129 mg/dl
/> .>
/> .> < 70 mg/dl: Children were .5% to .8%, lower than my 1.3%,
/> .> Adults were .6% to 1.4%, higher than my 1.3% only when
/> .> their target glucose was 130 mg/dl
/> .>
/> .> 70-180 mg/dl: 53.5% to 75.1%, much lower than my 90.7%
/> .>
/> .> > 180 mg/dl: Alarmingly high 23.4% to 46.7%, much higher
/> .> than my 8%
/> .>
/> .> So, unless the Omnipod 5 (Horizon) can
/> .> mate to the glucose levels I have now,
/> .> I'd be hard pressed to use it, albeit I'd
/> .> enjoy being able to sleep without waking
/> .> up 4 times each night, but I'd fear its ap-
/> .> parent propensity for much higher glucose
/> .> levels than I'm able to achieve now.
/> .>
/> .> I'd probably have to override whatever set-
/> .> tings they used in their test, because their
/> .> time in range is far lower than what I have
/> .> now and their time > 180 mg/dl is much
/> .> higher than what I have now, unacceptably
/> .> higher.
/> .>
/> .> I have to add, see the following post for
/> .> details on what the glucose levels are of
/> .> individuals with a fully functional pancreas,
/> .> and note that my glucose levels, while
/> .> considerably better than the Omnipod 5
/> .> (Horizon) glucose levels, mine are ...
/> .>
/> .> ... disappointingly short of the perfectly
/> .> controlled glucose levels that those with
/> .> a fully functional pancreas achieve with-
/> .> out one iota of effort on their part.
/> .> https://groups.google.com/g/misc.health.diabetes/c/4E_1OM3ZzSk/m/LIj0zVsWAwAJ
/> .>
/> .> Put another way, I'm disappointed in what I
/> .> see for the closed-loop Omnipod 5 (Horizon),
/> .> and Islit individuals need something far better
/> .> to have glucose levels like what we had prior
/> .> to Insulitis destroying our beta cells (the pri-
/> .> mary cause of Islit, but other infrequent ...
/> .>
/> .> ... causes can result in the near-total to total
/> .> loss of endogenous insulin).
/> .>
/> .> ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
/> .>
/> .> INSULINITIS (ISLIT)
/> .>
/> .> New SUPERIOR clarifying name for near-
/> .> total to total loss of endogenous insulin
/> .> https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg
/> .>
/> .> The overwhelming majority of Islit caused by
/> .> autoimmune attacks on pancreatic beta cells
/> .> (Insulitis Islit) but there are
/> .>
/> .> o 15 specific types of rapid onset Islit, a
/> .> rare condition (only present in < one-half
/> .> of 1% of Americans & in a much lower rate
/> .> in most of the world), when present is typ-
/> .> ically diagnosed at age under 30
/> .> (50% at age < 18, 20% at age 19 to 29)
/> .>
/> .> o 1 slow onset specific type, Latent Autoim-
/> .> mune Islit, frequency unknown but per a
/> .> recent report, misdiagnosed as Cellosis
/> .> (new clarifying name for type 2 diabetes)
/> .> almost 40% of the time due to its slow
/> .> onset and its occurrence typically at age
/> .> over 30
/> .>
/> .> Old outdated anachronistic name for Islit is
/> .> type 1 diabetes, confusing in that diabetes
/> .> without clarifier is often used to describe
/> .> this condition which is 1 of the 7 Disparate
/> .> High Glucose Conditions (DHGCs).
/> .>
/> .> That makes figuring out which DHGC is actu-
/> .> ally being referred to (and it can be any one,
/> .> or some, or all of them when the diabetes
/> .> or diabetic word is used without clarifier)
/> .> confusing / difficult:
/> .> https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg
/> .> https://prohuman.net/pix2/diabetesdiabeticconfusion.jpg
/> .> https://prohuman.net/pix2/diabetesdiabeticendingthemisunderstanding.jpg
/> .>
/> .> - - -
/> .>
/> .> Insulin / Insulin Pump / CGM I use
/> .>
/> .> Fiasp Ultra-Fast-Acting Insulin in a
/> .> tubeless Omnipod insulin pump catheter
/> .> placed into skin / pod with adhesive
/> .> stuck onto skin every 80 hours, control
/> .> via PDM (Personal Data Manager)
/> .> https://prohuman.net/pix2/Fiaspinsulin_tubelessOmnipodDASHinsulinpump.jpg
/> .>
/> .> Dexcom G6 CGM (continuous glucose monitor)
/> .> https://prohuman.net/pix2/Dexcom_G6_CGM.jpg
/> .>
/> .> ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
_
Jun 26, 2021, 10:12:22 PM6/26/21
to
Follow-up 3: Link to article including key infor-
mation missing in the previous follow-up:
From previous post:
. Unlike the plethora of details in the original
. post in this thread, the following report has
. a few sparse details. I expect a plethora of
. details will appear in the future.
.
. using a term I haven't seen before, Automated
. Insulin Delivery (AID) System, not mentioning
. that to auto-adjust basal insulin dosaging, the
. glucose levels from a tied-in CGM are critical.
.
. their tests, ignoring Islit individuals whose
. current glucose levels are < 7, < 6.5, < 6,
. & < 5.7 (the good-to-great HbA1c gang).
.
. nore Islit individuals with HbA1c levels men-
. tioned. One would hope that those individuals
. would also have significant benefits (less ...
. via Omnipod 5, but unfortunately, their test-
. ing ignores the good-to-great-HbA1c gang.
https://www.contemporarypediatrics.com/view/evaluation-of-the-omnipod-5-automated-insulin-delivery-system-in-very-young-children-with-type-1-diabetes
.... The delivery system communicates directly
with Dexcom G6 sensor for a continuous glu-
cose monitor. An algorithm is built into the pod,
so that the insulin delivery can continue without
the handheld controller nearby.
The Omnipod 5 app is used to start and stop
atuomated mode, deliver boluses, view data,
and change settings. It includes customizable
glucose targets, with a HypoProtect feature
for times of elevated hypoglycemic risk (such
as exercise). ...
~~~
Link to previous follow-up which included
all 3 previous posts in this thread:
https://groups.google.com/g/misc.health.diabetes/c/nd6zyPma6Ak/m/0hFLkZs6BwAJ
~. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
~. Diabetes Bubble / Diabetes Bubble Burst
~. https://prohuman.net/diabetesbubblediabetesbubbleburst.htm
~.
~. C.ure I.nsulinitis A.ssociation
~. https://prohuman.net/cureinsulinitisassociation.htm
~.
~. Glucose Anomalies Research regarding
~. Potential Cures / Improvements in Treatments
~. https://prohuman.net/glucoseanomaliesresearch.htm
~. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mation missing in the previous follow-up:
From previous post:
. Unlike the plethora of details in the original
. post in this thread, the following report has
. a few sparse details. I expect a plethora of
. details will appear in the future.
.
. Odd, they don't mention the critical continu-
. ous glucose monitor tie-in to the Omnipod 5,
. using a term I haven't seen before, Automated
. Insulin Delivery (AID) System, not mentioning
. that to auto-adjust basal insulin dosaging, the
. glucose levels from a tied-in CGM are critical.
.
. Another glaring shortcoming, they focus on
. Islit individuals with high glucose levels in
. their tests, ignoring Islit individuals whose
. current glucose levels are < 7, < 6.5, < 6,
. & < 5.7 (the good-to-great HbA1c gang).
.
. I'm disappointed that they are so focused
. on Islit individuals with HbA1c > 7 they ig-
. nore Islit individuals with HbA1c levels men-
. tioned. One would hope that those individuals
. would also have significant benefits (less ...
.
. ... hypoglycemia, more time in range, less
. hyperglycemia, as good or better HbA1c)
. ... hypoglycemia, more time in range, less
. via Omnipod 5, but unfortunately, their test-
. ing ignores the good-to-great-HbA1c gang.
https://www.contemporarypediatrics.com/view/evaluation-of-the-omnipod-5-automated-insulin-delivery-system-in-very-young-children-with-type-1-diabetes
.... The delivery system communicates directly
with Dexcom G6 sensor for a continuous glu-
cose monitor. An algorithm is built into the pod,
so that the insulin delivery can continue without
the handheld controller nearby.
The Omnipod 5 app is used to start and stop
atuomated mode, deliver boluses, view data,
and change settings. It includes customizable
glucose targets, with a HypoProtect feature
for times of elevated hypoglycemic risk (such
as exercise). ...
~~~
Link to previous follow-up which included
all 3 previous posts in this thread:
https://groups.google.com/g/misc.health.diabetes/c/nd6zyPma6Ak/m/0hFLkZs6BwAJ
~. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
~. Diabetes Bubble / Diabetes Bubble Burst
~. https://prohuman.net/diabetesbubblediabetesbubbleburst.htm
~.
~. C.ure I.nsulinitis A.ssociation
~. https://prohuman.net/cureinsulinitisassociation.htm
~.
~. Glucose Anomalies Research regarding
~. Potential Cures / Improvements in Treatments
~. https://prohuman.net/glucoseanomaliesresearch.htm
~. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
_
Jun 27, 2021, 1:23:29 PM6/27/21
to
Follow-up 4: Additional information / correction
regarding 80 children involved in the study who
were aged between 2.0 and 5.9 years, with 20%
being between 2 and 4 years.
https://diabetes.medicinematters.com/ada-2021/artificial-pancreas-systems/omnipod-5-insulin-type-1-diabetes-preschoolers/19297076
Their baseline glycated hemoglobin (HbA1c) levels
ranged from 5.4% to 10.2% (36 to 88 mmol/mol),
and 15% were using multiple daily insulin injections,
rather than an insulin pump.
The Omnipod 5 system has customizable glucose
targets from 110 to 150 mg/dL (6.1–8.3 mmol/L),
which can be varied according to the time of day.
The most used target was 120 mg/dL (6.7 mmol/L),
which was used for 42% of cumulative study time,
followed by the 110 mg/dL target, accounting for
33% of the time.
On Saturday, June 26, 2021 at 9:12:22 PM UTC-5, _ wrote:
.> Follow-up 3: Link to article including key infor-
.> mation missing in the previous follow-up:
.>
.> From previous post:
.>
/> . Unlike the plethora of details in the original
/> . post in this thread, the following report has
/> . a few sparse details. I expect a plethora of
/> . details will appear in the future.
/> .
/> . Odd, they don't mention the critical continu-
/> . ous glucose monitor tie-in to the Omnipod 5,
/> . using a term I haven't seen before, Automated
/> . Insulin Delivery (AID) System, not mentioning
/> . that to auto-adjust basal insulin dosaging, the
/> . glucose levels from a tied-in CGM are critical.
/> .
/> . Another glaring shortcoming, they focus on
/> . Islit individuals with high glucose levels in
/> . their tests, ignoring Islit individuals whose
/> . current glucose levels are < 7, < 6.5, < 6,
/> . & < 5.7 (the good-to-great HbA1c gang).
Apparently, based on the excerpt above, they
did include the good-to-great HbA1c gang but
did not include any details on the impact of
using the Omnipod 5 on HbA1c, hypoglycemia,
time in range, and hyperglycemia among the
good-to-great HbA1c gang.
Hopefully, at some point in the future, details
on that will be available as were provided in
an earlier study on Omnipod 5 usage in Jan-
uary 2021.
/> .
/> . I'm disappointed that they are so focused
/> . on Islit individuals with HbA1c > 7 they ig-
/> . nore Islit individuals with HbA1c levels men-
/> . tioned. One would hope that those individuals
/> . would also have significant benefits (less ...
/> .
/> . ... hypoglycemia, more time in range, less
/> . hyperglycemia, as good or better HbA1c)
/> . via Omnipod 5, but unfortunately, their test-
/> . ing ignores the good-to-great-HbA1c gang.
.> https://www.contemporarypediatrics.com/view/evaluation-of-the-omnipod-5-automated-insulin-delivery-system-in-very-young-children-with-type-1-diabetes
.>
.> .... The delivery system communicates directly
.> with Dexcom G6 sensor for a continuous glu-
.> cose monitor. An algorithm is built into the pod,
.> so that the insulin delivery can continue without
.> the handheld controller nearby.
.>
.> The Omnipod 5 app is used to start and stop
.> atuomated mode, deliver boluses, view data,
.> and change settings. It includes customizable
.> glucose targets, with a HypoProtect feature
.> for times of elevated hypoglycemic risk (such
.> as exercise). ...
.>
.> ~~~
.>
.> Link to previous follow-up which included
.> all 3 previous posts in this thread:
.> https://groups.google.com/g/misc.health.diabetes/c/nd6zyPma6Ak/m/0hFLkZs6BwAJ
/> ~. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
/> ~. Diabetes Bubble / Diabetes Bubble Burst
/> ~. https://prohuman.net/diabetesbubblediabetesbubbleburst.htm
/> ~.
/> ~. C.ure I.nsulinitis A.ssociation
/> ~. https://prohuman.net/cureinsulinitisassociation.htm
/> ~.
/> ~. Glucose Anomalies Research regarding
/> ~. Potential Cures / Improvements in Treatments
/> ~. https://prohuman.net/glucoseanomaliesresearch.htm
/> ~. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
regarding 80 children involved in the study who
were aged between 2.0 and 5.9 years, with 20%
being between 2 and 4 years.
https://diabetes.medicinematters.com/ada-2021/artificial-pancreas-systems/omnipod-5-insulin-type-1-diabetes-preschoolers/19297076
Their baseline glycated hemoglobin (HbA1c) levels
ranged from 5.4% to 10.2% (36 to 88 mmol/mol),
and 15% were using multiple daily insulin injections,
rather than an insulin pump.
The Omnipod 5 system has customizable glucose
targets from 110 to 150 mg/dL (6.1–8.3 mmol/L),
which can be varied according to the time of day.
The most used target was 120 mg/dL (6.7 mmol/L),
which was used for 42% of cumulative study time,
followed by the 110 mg/dL target, accounting for
33% of the time.
On Saturday, June 26, 2021 at 9:12:22 PM UTC-5, _ wrote:
.> Follow-up 3: Link to article including key infor-
.> mation missing in the previous follow-up:
.>
.> From previous post:
.>
/> . Unlike the plethora of details in the original
/> . post in this thread, the following report has
/> . a few sparse details. I expect a plethora of
/> . details will appear in the future.
/> .
/> . Odd, they don't mention the critical continu-
/> . ous glucose monitor tie-in to the Omnipod 5,
/> . using a term I haven't seen before, Automated
/> . Insulin Delivery (AID) System, not mentioning
/> . that to auto-adjust basal insulin dosaging, the
/> . glucose levels from a tied-in CGM are critical.
/> .
/> . Another glaring shortcoming, they focus on
/> . Islit individuals with high glucose levels in
/> . their tests, ignoring Islit individuals whose
/> . current glucose levels are < 7, < 6.5, < 6,
/> . & < 5.7 (the good-to-great HbA1c gang).
Apparently, based on the excerpt above, they
did include the good-to-great HbA1c gang but
did not include any details on the impact of
using the Omnipod 5 on HbA1c, hypoglycemia,
time in range, and hyperglycemia among the
good-to-great HbA1c gang.
Hopefully, at some point in the future, details
on that will be available as were provided in
an earlier study on Omnipod 5 usage in Jan-
uary 2021.
/> .
/> . I'm disappointed that they are so focused
/> . on Islit individuals with HbA1c > 7 they ig-
/> . nore Islit individuals with HbA1c levels men-
/> . tioned. One would hope that those individuals
/> . would also have significant benefits (less ...
/> .
/> . ... hypoglycemia, more time in range, less
/> . hyperglycemia, as good or better HbA1c)
/> . via Omnipod 5, but unfortunately, their test-
/> . ing ignores the good-to-great-HbA1c gang.
.> https://www.contemporarypediatrics.com/view/evaluation-of-the-omnipod-5-automated-insulin-delivery-system-in-very-young-children-with-type-1-diabetes
.>
.> .... The delivery system communicates directly
.> with Dexcom G6 sensor for a continuous glu-
.> cose monitor. An algorithm is built into the pod,
.> so that the insulin delivery can continue without
.> the handheld controller nearby.
.>
.> The Omnipod 5 app is used to start and stop
.> atuomated mode, deliver boluses, view data,
.> and change settings. It includes customizable
.> glucose targets, with a HypoProtect feature
.> for times of elevated hypoglycemic risk (such
.> as exercise). ...
.>
.> ~~~
.>
.> Link to previous follow-up which included
.> all 3 previous posts in this thread:
.> https://groups.google.com/g/misc.health.diabetes/c/nd6zyPma6Ak/m/0hFLkZs6BwAJ
/> ~. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
/> ~. Diabetes Bubble / Diabetes Bubble Burst
/> ~. https://prohuman.net/diabetesbubblediabetesbubbleburst.htm
/> ~.
/> ~. C.ure I.nsulinitis A.ssociation
/> ~. https://prohuman.net/cureinsulinitisassociation.htm
/> ~.
/> ~. Glucose Anomalies Research regarding
/> ~. Potential Cures / Improvements in Treatments
/> ~. https://prohuman.net/glucoseanomaliesresearch.htm
/> ~. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
0 new messages